Wall Street analysts remain optimistic about Eli Lilly’s future prospects after Bernstein SocGen Group reaffirmed its Outperform rating on the pharmaceutical giant with a price target of $1,300. The endorsement comes as the company pursues an ambitious strategy to expand its incretin medications far beyond their current use in obesity treatment. The $1,300 price target […]

The postConfident analyst sees Eli Lilly stock soaring by 31%appeared first onRolling Out.